Lineage Cell Therapeutics (LCTX)

• Market cap: $276M
• 1 day: 0.93%
• 5 days: 2.83%
• 1 month: 5.83%
• 3 months: -15.5%
• 6 months: -40.11%
• Year to date: -33.54%
• 1 year: -6.84%
• 5 years: -55.51%
• 10 years: -59.02%
• Sector: Healthcare
• Industry: Drug Manufacturers - General

About: Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.

Employees: 77